{"pmid":32451971,"title":"Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?","text":["Hyponatremia, IL-6, and SARS-CoV-2 (COVID-19) infection: may all fit together?","J Endocrinol Invest","Berni, A","Malandrino, D","Parenti, G","Maggi, M","Poggesi, L","Peri, A","32451971"],"journal":"J Endocrinol Invest","authors":["Berni, A","Malandrino, D","Parenti, G","Maggi, M","Poggesi, L","Peri, A"],"date":"2020-05-27T11:00:00Z","year":2020,"_id":"32451971","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1007/s40618-020-01301-w","keywords":["covid-19","hyponatremia","interleukin-6 (il-6)","pao2/fio2 ratio","tocilizumab"],"topics":["Treatment"],"weight":1,"_version_":1667881798392086529,"score":9.490897,"similar":[{"pmid":32479986,"title":"Type 3 hypersensitivity in COVID-19 vasculitis.","text":["Type 3 hypersensitivity in COVID-19 vasculitis.","Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden around the world. For the first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening escalation from type 2T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine, from the smooth muscle cells of blood vessels.","Clin Immunol","Roncati, Luca","Ligabue, Giulia","Fabbiani, Luca","Malagoli, Claudia","Gallo, Graziana","Lusenti, Beatrice","Nasillo, Vincenzo","Manenti, Antonio","Maiorana, Antonio","32479986"],"abstract":["Coronavirus Disease 2019 (COVID-19) is an ongoing public health emergency and new knowledge about its immunopathogenic mechanisms is deemed necessary in the attempt to reduce the death burden around the world. For the first time in worldwide literature, we provide scientific evidence that in COVID-19 vasculitis a life-threatening escalation from type 2T-helper immune response (humoral immunity) to type 3 hypersensitivity (immune complex disease) takes place. The subsequent deposition of immune complexes inside the vascular walls is supposed to induce a severe inflammatory state and a cytokine release syndrome, whose interleukin-6 is the key myokine, from the smooth muscle cells of blood vessels."],"journal":"Clin Immunol","authors":["Roncati, Luca","Ligabue, Giulia","Fabbiani, Luca","Malagoli, Claudia","Gallo, Graziana","Lusenti, Beatrice","Nasillo, Vincenzo","Manenti, Antonio","Maiorana, Antonio"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32479986","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.clim.2020.108487","keywords":["coronavirus disease 2019 (covid-19)","immune complex disease","interleukin-6 (il-6)","severe acute respiratory syndrome coronavirus 2 (sars-cov-2)","type iii hypersensitivity","vasculitis"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668437835030462464,"score":60.446728},{"pmid":32462717,"title":"COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","text":["COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.","COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved.","J Med Virol","Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy","32462717"],"abstract":["COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. In order to reduce the cytokine storm, we would like to propose the IL6 receptor antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL6 receptor antagonists for the therapy of cytokine storm syndrome SARS-CoV-2 infected persons to enhance the therapeutic options for cytokine storm. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Chakraborty, Chiranjib","Sharma, Ashish Ranjan","Bhattacharya, Manojit","Sharma, Garima","Lee, Sang-Soo","Agoramoorthy, Govindasamy"],"date":"2020-05-29T11:00:00Z","year":2020,"_id":"32462717","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1002/jmv.26078","keywords":["cytokine storm","il6r antagonist","sarilumab","therapeutic option","tocilizumab"],"e_drugs":["tocilizumab","sarilumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668079521235992576,"score":58.46015},{"pmid":32421092,"pmcid":"PMC7224649","title":"SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","text":["SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc.","Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway.","Cytokine X","Magro, Giuseppe","32421092"],"abstract":["Since the outbreak of COVID-19 many studies have been published showing possible therapies, here the author discusses the end of stage disease related drugs, like Tocilizumab which is currently being used in ARDS patients. In some patients, disease progression leads to an enormous secretion of cytokines, known as cytokine storm, among those cytokines IL-6 plays an important role. Here the author shows how IL-6 has both pro and anti-inflammatory properties, depending on the pathway of transduction: soluble (trans-signaling) or membrane-related (classic signaling), and suggests how targeting only the pro-inflammatory pathway, with SGP130Fc, could be a better option then targeting them both. Other possible IL-6 pathway inhibitors such as Ruxolitinib and Baricinitib are then analyzed, underlying how they lack the benefit of targeting only the pro-inflammatory pathway."],"journal":"Cytokine X","authors":["Magro, Giuseppe"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32421092","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.cytox.2020.100029","keywords":["baricitinib","covid-19","il-6","il-6 trans-signaling","interleukin-6","ruxolitinib","sars-cov-1","sars-cov-2","sgp130fc","tocilizumab","coronavirus","coronaviruses","drugs","strategies","targets","therapies"],"e_drugs":["INCB018424","tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667159284554661888,"score":58.004066},{"pmid":32378647,"title":"Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?","text":["Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far?","The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of \"cytokine storm\" in COVID-19. However, we still lack reliable studies to verify \"cytokine storm\" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated.","Drug Discov Ther","Zhang, Yuanyuan","Zhong, Yanyan","Pan, Lin","Dong, Jing","32378647"],"abstract":["The world is in the midst of the coronavirus disease 2019 (COVID-19) pandemic. Interleukin 6 (IL-6) inhibitor (tocilizumab) had been suggested for the treatment of acute respiratory distress syndrome (ARDS) patients based on the concept of \"cytokine storm\" in COVID-19. However, we still lack reliable studies to verify \"cytokine storm\" in COVID-19 pneumonia. Furthermore, IL-6 inhibitor has potential hazards of inducing infectious diseases. The efficacy of IL-6 monoclonal antibody-directed therapy remains to be fully evaluated."],"journal":"Drug Discov Ther","authors":["Zhang, Yuanyuan","Zhong, Yanyan","Pan, Lin","Dong, Jing"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378647","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.5582/ddt.2020.03006","keywords":["coronavirus","cytokine storm","pneumonia","tocilizumab"],"e_drugs":["tocilizumab"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097302917120,"score":55.115963},{"pmid":32396497,"title":"Covid-19 associated SIADH; a clue in the times of pandemic!","text":["Covid-19 associated SIADH; a clue in the times of pandemic!","Am J Physiol Endocrinol Metab","Yousaf, Zohaib","Al-Shokri, Shaikha D","Al-Soub, Hussam","Mohamed, Mouhand F H","32396497"],"journal":"Am J Physiol Endocrinol Metab","authors":["Yousaf, Zohaib","Al-Shokri, Shaikha D","Al-Soub, Hussam","Mohamed, Mouhand F H"],"date":"2020-05-13T11:00:00Z","year":2020,"_id":"32396497","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1152/ajpendo.00178.2020","keywords":["covid-19","hyponatremia","siadh"],"weight":0,"_version_":1666627827883048960,"score":54.65207}]}